PLA2G7 and Cognitive impairment: Another study has suggested that high plasma lipoprotein-associated phospholipase A2 (Lp PLA2) may be a potential and specific biomarker to predict cognitive impairment in CMB patients (ROC = 0.693, p < 0.0001), and the number of CMBs significantly mediates the relationship between Lp PLA2 and cognitive decline ((indirect effect = −0.017, p = 0.031) [55].